Table 2.

Change of disease activity and patient-reported symptoms at the different timepoints compared to baseline.

	W12		W24		W36		W48
	CT-P10	RTX originator	CT-P10	RTX originator	CT-P10	RTX originator	CT-P10	RTX originator
ΔESSDAI, mean (SD)	−2.75 (2.37)	−3.00 (2.18)	−5.12 (2.10)	−5.89 (4.99)	−5.12 (2.10)	−7.67 (5.59)	−5.62 (2.26)	−8.44 (5.03)
ΔclinESSDAI mean (SD)	−2.75 (2.37)	−3.11 (2.26)	−5.12 (2.10)	−5.89 (4.99)	−5.12 (2.10)	−7.67 (5.59)	−5.62 (2.26)	−8.44 (5.03)
ΔESSPRI mean (SD)	−4.1 (4.4)	−3.15 (3.1)	−1.6 (2.3)	−3.3 (2.9)	−4.5 (2.9)	−4.3 (2.6)	−3.46 (2.9)	−3.33 (0.91)

RTX, rituximab; ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; clin, clinical; ESSPRI, EULAR Sjögren's Syndrome Patient-Reported Index.